Astellas/Medivation <10K >50K <10K Genentech/Roche <10K Pfizer <10K Sydes Matt Astellas >50K Janssen >50K Novartis >50K Pfizer >50K Sanofi-Aventis >50K Tannock Ian Ipsen Pharma <10K Janssen <10K (Chair IDMC for a phrase III prostate cancer trials) Roche <10K (Member IDMC for a phase III prostate trial) Tombal Bertrand Astellas 10-50K 10-50K 10-50K 10-50K Bayer <10K <10K Amgen <10K <10K Ferring <10K 10-50K 10-50K >50K <10K Sanofi Aventis 10-50K 10-50K Valdagni Janssen <10K Riccardo Ipsen <10K Bayer <10K Wiegel Thomas Ipsen <10K Hexal <10K
Astellas/Medivation Genentech/Roche Pfizer <10K <10K <10K <10K >50K Sydes Matt Astellas Janssen Novartis Pfizer Sanofi-Aventis >50K >50K >50K >50K >50K Tannock Ian Ipsen Pharma Janssen Roche <10K <10K (Chair IDMC for a phrase III prostate cancer trials) <10K (Member IDMC for a phase III prostate trial) Tombal Bertrand Astellas Bayer Amgen Ferring Sanofi Aventis 10-50K <10K <10K 10-50K 10-50K <10K 10-50K 10-50K 10-50K 10-50K >50K 10-50K <10K <10K <10K Valdagni Riccardo Janssen Ipsen Bayer <10K <10K <10K Wiegel Thomas Ipsen Hexal <10K <10K